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Background: We used 3-deoxy-3-18F-fluorothymidine (FLT) PET-
CT to delineate biological tumour volume in thoracic oesophageal
carcinoma, for a treatment planning simulation. We compared
results with that of 18F-fluorodeoxyglucose (FDG) PET-CT, on the
basis of dosimetric analysis.
Methods: 22 patients with oesophageal squamous-cell carci-
noma detected by FLT and FDG PET-CT were enrolled. We used
the treatment planning system to compare hypothetical treat-
ment plans based on the optimal threshold for standard uptake
value of FLT and FDG PET-CT. We compared parameters in dose–
volume histograms of the two groups, planning fields in similar
directions and ensuring the prescribed dose line surrounded
95% of the target volume.
Findings: Gross tumour volume, clinical target volume, and
planning target volume were less with FLT than with FDG PET-
CT imaging. The conformity index and homogeneity index did
not differ significantly between FLT and FDG PET-CT treatment
planning. The difference in V20 of bilateral lung, V40 of heart,
and maximum dose received by the spinal cord did not differ sig-
nificantly between FLT and FDG. Values for mean lung dose, V5,
V10, V30, V40, and V50 of bilateral lung, and mean heart dose and
V30 of heart were significantly lower with FLT PET-CT based plan-
ning than with FDG PET-CT (t = -5.442 to 2.637, p < 0.05).
Interpretation: Treatment planning based on FLT PET-CT had
potential benefits for some organs at risk, such as lungs and
heart.
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CANCER CENTRE IN NORTHEAST INDIA
J. Purkayastha *, B.K. Das, B.B. Borthakur, A. Talukdar,
M. Ahmed. Department of Surgical Oncology, Dr. B Borooah Cancer
Institute, Guwahati, Assam, India
Background: Tumours of the breast have become one of the
most common malignancies in India in recent years, and seem
to be increasing. Common malignancies affecting the breast are
carcinoma and sarcoma, including phyllodes tumour. Because
of a lack of awareness in the general population, patients present
late and with large advanced tumours. Surgery for large tumours
leads to extensive defects that may not be suitable for primary
closure. Extensive, complex surgical procedures are not suitable
for our centre because of a lack of resources and time constraints.
We share our experience of closure of such defects using a simple
procedure, the thoraco-abdominal (TA) flap.
Methods: Between January, 2003, and December, 2010, a total of
1232 patients had surgery for breast tumours at our centre. Of
these, 912 (74%) of patients had amastectomy. 78 (8.5%) of patients
had a large post-mastectomy defect that could not be closed pri-
marily. Soft-tissue cover using the TA flapwas done for all of these
patients. The TA flap is a rotation-advancement variant of the fas-
cio-cutaneous flap, with random pattern blood supply.
Findings: Primary healing could be achieved in 73 (94%) of
patients who had TA flap cover. Three patients had marginal
necrosis that responded to conservative treatment. Two patients
developed major necrosis with loss of TA flap and needed salvage
myocutaneous flap repair. All patients were able to receive the
planned adjuvant chemo and/or radiation therapy.
Interpretation: The aim of surgery in large advanced breast
tumours is adequate disease extirpation with early recovery, so
that adjuvant therapy can be done to improve survival. The TA
flap is a simple, safe, reliable, and effective technique with mini-
mum morbidity for coverage of large post-mastectomy defects,
and is particularly suited for surgeons and patients in our region.
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Background: Hypoxia has been shown to cause tumour resis-
tance to radiation and chemotherapy. Treatment failure in large
tumours of locally advanced cervical cancer is associated with
intratumoral hypoxic circumstances. We investigated the associ-
ation between hypoxia, angiogenesis, proliferation, and tumour
volume in patients with locally advanced cervical cancer, and
evaluated the effectiveness of carbogen-nicotinamide (CON) as
a hypoxia modifier to enhance cell oxygenation.
Methods: 89 patients with locally advanced cervical cancer
treated at the Department of Radiotherapy, Cipto Mangunkusumo
General Hospital, Jakarta, were included in this study. Patients
were divided into two groups. Group 1 consisted of 29 patients
who received radiotherapy combined with CON (RT + CON); group
2 had 60 patients who received chemo-radiotherapy (CRT) with
cis-platinum. Group 2 was randomly divided into two subgroups,
who received CRT plus CON or CRT alone. Biopsy specimens were
taken to identify CA9 as a hypoxia marker, vascular endothelial
growth factor (VEGF) as an angiogenesis marker, and S-phase
fraction (SPF) as a proliferation marker. Analysis was done to
evaluate the correlation between the three markers, between
the markers and tumour volume, and the benefit of introducing
CON.
Findings: A significant positive correlation was noted among
pre-irradiated tumour volume and two markers: CA9 (r = 0.514,
p = 0.007) and SPF (r = 0.422, p = 0.032), but there was a weak and
non-significant correlation between tumour volume and VEGF
(r = 0.422, p = 0.114). Significant correlations among the markers
were also found: CA9 with VEGF (r = 0.678, p = 0.000), VEGF with
SPF (r = 0.475, p = 0.005), and SPF with CA9 (r = 0.510, p = 0.002).
CON effectiveness was analysed by evaluating treatment
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response. 69.2% in the RT + CON group had a complete response.
90.9% of the CRT + CON group and 63.6% of the CRT group had a
complete response (statistically significant at p = 0.031). No signif-
icant correlation was found between RT + CON and CRT
(p = 0.313).
Interpretation: This study shows that hypoxia and cell prolifer-
ation increase with tumour volume. The response to radiation
increased significantly in the group who received CON as part of
treatment. This finding shows that CON has an important role
in breaking the cycle that causes radio-chemoresistance. There-
fore, CON in combination with RT can be considered for those
who are not eligible for or refuse chemotherapy.
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China
Background: Nischarin, a novel protein, was originally identi-
fied as an a5b1 interacting protein and has been shown to inhibit
cell motility through inhibition of the Rac/PAK/LIMK/Coffinin
pathway. Nischarin blocks tumour-cell migration and invasion
in breast-cancer cell line MCF7.
Methods: To further study the role of Nischarin in breast can-
cer, we evaluated expression levels by immunohistochemistry
in 36 breast-cancer and 20 normal-breast tissue sections. We
also looked at the expression pattern using the NCBI-GEO
database.
Findings: Nischarin expression was positive in 27.8% (10/36)
breast-cancer tissues, which was significantly lower than the per-
cent expressing the protein in normal breast tissues (55%, 11/20;
p < 0.05). Furthermore, expression of Nischarin in breast cancer
was associated with oestrogen-receptor (ER) status. Nischarin
was expressed in 60% (6/10) ER-positive tumour tissues, whereas
in ER-negative tumour tissues, positivity of Nischarin was only
15.4% (4/26; p < 0.05). Concordant with immunostaining, NCBI-
GEO analysis confirmed that Nischarin was poorly expressed in
HER2-positive and/or ER-negative highly invasive breast cancer,
and was expressed at higher levels in other cancerous cells and
in normal breast tissue.
Interpretation: These data suggest that Nischarin has an
important role in breast-cancer progression, and it might be a
potential tumour suppressor. The relationship between Nischa-
rin and breast cancer, and the mechanism, are currently being
studied.
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